A Phase 1/2 interventional study of Nilotinib in Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) and Hypereosinophilic Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 101 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 3rd largest by enrollment, is one of 4 that started in 2005, is one of 6 in phase 1/2, and was the 2nd registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 507 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 6th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2005, is one of 6 in phase 1/2, and was the 7th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity, and pharmacokinetics of AMN107 in six groups of patients with one of the following conditions:
Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1)
Group A - Imatinib failure only (arms 2, 3 and 4)
Group B - Imatinib and other TKI failure (arms 2, 3 and 4)
Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5)
Systemic mastocytosis (Sm) (arm 6)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Main inclusion criteria include:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Imatinib-resistant / intolerant PH+ CML-CP patients
Drug: Nilotinib
Imatinib-resistant / intolerant PH+ CML-AP patients
Drug: Nilotinib
Imatinib-resistant / intolerant PH+ CML-CP patients
Drug: Nilotinib
Number of Participants With Major Cytogenetic Response (MCyR)
Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Number of Participants Confirmed Overall Hematological Response (Phase II)
Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver). Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Number of Participants With Overall Major Cytogenetic Responses (Phase II)
Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and \>0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Number of Participants With Complete Hematologic Response (Phase II)
A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; \< 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Participants With (MMR) Major Molecular Response (Phase II)
MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Time to Progression (TTP) (Phase II)
Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death. Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Overall Survival (OS) (Phase II)
OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.
Time frame: Up to End of the Treatment (Approximately 7.5 years)
Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety
Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.
Time frame: From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)
The study was conducted at 100 centers in 22 countries.
| Milestone | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Started | 321 | 137 | 49 |
| Entered extension study | 106 | 15 | 15 |
| Completed | 67 | 8 | 8 |
| Not completed | 254 | 129 | 41 |
| Withdrew: Discontinued in core study without entering the extension study | 215 | 122 | 34 |
| Withdrew: Abnormal laboratory values | 1 | 0 | 0 |
| Withdrew: Administrative problems | 2 | 0 | 1 |
| Withdrew: Adverse event | 10 | 2 | 3 |
| Withdrew: Death | 4 | 0 | 0 |
| Withdrew: Disease progression | 12 | 4 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Withdrew: Patient withdrew consent | 6 | 1 | 0 |
Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).
| Participants | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Number of Participants With Major Cytogenetic Response (MCyR) | 191 | 44 | 22 |
Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver). Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.
| Participants | CML-AP With Prior Imatinib Only |
|---|---|
| Number of Participants Confirmed Overall Hematological Response (Phase II) | 76 |
Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and \>0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).
| participants | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Number of Participants With Overall Major Cytogenetic Responses (Phase II) | 191 | 44 | 22 |
A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; \< 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.
| participants | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Number of Participants With Complete Hematologic Response (Phase II) | 158 | 76 | 27 |
MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.
| Participants | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only |
|---|---|---|
| Participants With (MMR) Major Molecular Response (Phase II) | 106 | 18 |
Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death. Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).
| Months | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only |
|---|---|---|
| Time to Progression (TTP) (Phase II) | 55.6 (0.1 to 77.8) | 15.9 (0.1 to 75.7) |
OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.
| months | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Overall Survival (OS) (Phase II) | NA (77.93 to NA) | 47.54 (38.24 to 64.30) | NA (NA to NA) |
Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.
| Participants | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| Serious Adverse Events | 61 | 26 | 5 |
| Adverse Events | 57 | 17 | 7 |
Collected over From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CML-CP With Prior Imatinib Only | 13/321 (4%) | 146/321 (45.5%) | 319/321 (99.4%) |
| CML-AP With Prior Imatinib Only | 14/137 (10.2%) | 55/137 (40.1%) | 136/137 (99.3%) |
| CML-CP | 0/49 (0%) | 21/49 (42.9%) | 48/49 (98%) |
| Event | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/321 | 0/137 | 5/49 |
| PneumoniaInfections and infestations | 2/321 | 7/137 | 4/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/321 | 11/137 | 3/49 |
| AnaemiaBlood and lymphatic system disorders | 4/321 | 3/137 | 3/49 |
| NeutropeniaBlood and lymphatic system disorders | 7/321 | 8/137 | 0/49 |
| PyrexiaGeneral disorders | 9/321 | 6/137 | 2/49 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/321 | 3/137 | 2/49 |
| White blood cell count increasedInvestigations | 0/321 | 3/137 | 2/49 |
| Angina pectorisCardiac disorders | 12/321 | 0/137 | 0/49 |
| Myocardial infarctionCardiac disorders | 7/321 | 5/137 | 0/49 |
| Event | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 71/321 | 61/137 | 9/49 |
| ThrombocytopeniaBlood and lymphatic system disorders | 107/321 | 60/137 | 16/49 |
| RashSkin and subcutaneous tissue disorders | 118/321 | 39/137 | 20/49 |
| NauseaGastrointestinal disorders | 121/321 | 41/137 | 13/49 |
| PyrexiaGeneral disorders | 66/321 | 49/137 | 8/49 |
| HeadacheNervous system disorders | 114/321 | 0/137 | 11/49 |
| FatigueGeneral disorders | 105/321 | 28/137 | 13/49 |
| PruritusSkin and subcutaneous tissue disorders | 104/321 | 18/137 | 9/49 |
| NeutropeniaBlood and lymphatic system disorders | 57/321 | 39/137 | 15/49 |
| DiarrhoeaGastrointestinal disorders | 93/321 | 34/137 | 6/49 |
| Age, Customized(Participants) | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP | Total |
|---|---|---|---|---|
| <35 years | 22 | 8 | 3 | 33 |
| ≥35 to <55 years | 104 | 49 | 16 | 169 |
| ≥55 to <65 years | 97 | 39 | 12 | 148 |
| ≥65 years | 98 | 41 | 18 | 157 |
| Sex: Female, Male(Participants) | CML-CP With Prior Imatinib Only | CML-AP With Prior Imatinib Only | CML-CP | Total |
|---|---|---|---|---|
| Female | 159 | 61 | 25 | 245 |
| Male | 162 | 76 | 24 | 262 |
Showing the first 100 of 101 sites across 22 countries. Choose a country and city above to see the rest.
Ran from Apr 2005 to primary completion in Sep 2012, 89 months.
Results were first posted in Jun 2021, 8 years 9 months after primary completion.
Of 26 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's 89 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →